Placebo tablet

Repeatability Fiveteen placebo tablets are dissolved in water and spiked with the appropriate amount of a stock solution LO and/or HI so as to obtain the same concentrations of A and B as for the calibration solutions. Aliquots of each of these solutions are injected three times, for a total of 45 results of A and 45 for B. 

In Fig. 4.39, results for spiked placebo and for the verum tablets are given for compound A (bold lines) and B all horizontal bars should be at 100%, and the vertical lines should be centered at the same height. The gray trendlines, particularly for the LO- and Hl-range A-values indicate a systematic difference in response between tbe calibration solutions and the spiked placebo tablets (extraction efficiency, interference, etc.). For same ranges, the verum-tablets assays either underestimate the content of A by 4—5%, or A is underdosed. For compound A the repeatability figures are as follows (%-of-nom-inal, see file Fig4 39.dat), see Table 4.36. 

Figure 4.39. Variability of back calculated concentrations Concbc- For each concentration range five calibration points were measured, over which a separate regression was run (not shown). Placebo tablets were spiked to the same concentrations and measured in triplicate (short horizontal lines gray trend lines in background). Ten repeat determinations of actual product (vertical bars = Mean + SD) were done. The bold lines pertain to compound A in all concentration ranges, the thin lines to compound B (middle concentration range only).

Gotteries, J., Svenheden, A., Alpsten, M., Bake, B., Larsson, A. et al., Gastrointestinal transit of amoxicillin modified-release tablets and a placebo tablet including pharmacokinetic assessments of amoxicillin, Scand. J. Gastroenterol. 1996, 32, 49-53. 

Perkins, A. C., Wilson, C. G., Frier, M. et al., The use of scintigraphy to demonstrate the rapid esophageal transit of the oval film-coated placebo risedronate tablet compared to a round uncoated placebo tablet when administered with minimal volumes of water, Int. J. Pharm. 2001, 222, 295-303. 

These authors14 later report using the GC method for enteric coated tablets of erythromycin, giving a recovery of 99.8% and a coefficient of variation of 2.3% based on placebo tablets spiked with erythromycin. 

Tablet excipient interactions are occasionally observed when evaluating a drug product for purity. Since there are many excipients in a typical pharmaceutical tablet, known bands need to be identified to make it easier to evaluate for degradation products. Unfortunately, occasionally an inert excipient may react with a derivatizing agent used in TLC making this entity appear as a band that now needs to be identified. In Fig. 13.33, a placebo tablet, an extracted tablet, a handmade tablet blend of all components, and the drug substance standard are all applied to the same HPTLC plate and developed. These results alert the analyst to any excipients that may interfere in the evaluation of the tablet for purity. In this case, the only bands observed in the tablet blend and extracted tablet are the same bands seen in the tablet blend.

This same comparison however was then undertaken amongst the placebo patients. The good compliers on placebo only had a 15.1 per cent five year death rate while the poor compliers had a 28.3 per cent five year death rate with p = 00000000000000047 These placebo tablets are remarkable ... 

SST plus placebo the patients received 1 h of SST each week for 12 weeks with an experienced SST therapist. They also received placebo tablets. 

Psychotherapy plus placebo tablets the patients in this group received 1 h of individual, generally psyehodynamically orientated psychotherapy by experienced psychotherapists each week for 12 weeks. 

Mix the tablet test set prepared for sensitivity determination with placebo tablets. Pass this mixture completely through the metal check sensor at a mass flow necessary to cover the output (kg tablets/min) of the connected tablet press. 

Load the coating pan for 90% of the determined usable capacity with product (e.g., white placebo tablets). Subsequently add additional 10% of a different product (e.g., colored placebo tablets). Measure the time necessary to achieve a homogenous mixture by visual examination. 

In a randomized, placebo-controlled study in women who received leuprolide acetate depot 11.25 mg intramuscularly with tibolone 2.5 mg/day (n = 36), leuprolide acetate depot 11.25 mg with placebo (n = 37), or a placebo injection with placebo tablets (n = 39), irritable bowel syndrome related to the menstrual cycle improved in those who received leuprolide (5). There were hot flushes in those who took leuprolide compared with placebo no data were given about the frequency of hot flushes, but there were no withdrawals because of this symptom. Amenorrhea also occurred. Both flushing and amenorrhea are expected adverse effects of leuprolide. 

The impurity peak at RRT 0.40 was observed in all film-coated active and placebo tablets. The structural identification of this peak in the tablet samples was confirmed by both mass spectrometric and UV spectral analyses to be glyceryl triacetate, commonly known as triacetin, a component in the film coating used in these formulations. 

The impurity peak at RRT 3.4 was observed in all samples exposed to accelerated conditions. Structural identification of this peak could not be established since this component did not show any response in the mass spectral analysis. The presence of this peak in large amounts in both active and placebo tablets lead to the conclusion that the late eluting impurity observed at RRT 3.4 was indeed a degradation product of one or more of the excipient components present in the tablets. Because of the large amounts of this impurity in the samples, a study using the individual excipients was conducted to identify the source of this degradant. The study lead to the conclusion that the excipients exposed to accelerated conditions in powder form did not produce the degradation product. However, when the same excipients were compressed into pellets and exposed to the same conditions, lactose, microcrystaUine cellulose and croscarmellose sodium compacts showed the presence of the peak at RRT 3.4. 

The authors would like to thank Vincent Bobin for the solubility data for Compound A. The authors would also like to thank the following individuals for their work on Compound B described in this chapter Daniel Gierer for manufacture of the placebo tablets Amy Orce for her work on the extraneous syringe peak Thomas Sharp, George Horan, and Ronald Morris for their work on impurity identification and Cheryl Kirkman, Heidi O Donnell, Britt-Marie Otano, Doreathea Roberts, J. Sean Space, and Gregory Steeno for their work on the small volume dissolution method. In addition, the authors would like to thank Amanda Deal and Kelly Field for their work on the HPLC purity method development for the fixed combination tablet. 

Figure 12.2 (a) 13C CPMAS spectrum of a crushed placebo tablet showing the signals of the excipients only, (b) 13C CPMAS spectrum of a crashed tablet containing 2.5 w/w% unlabeled Org OD 14. The 13C signals of Org OD 14 are only just detectable, (c) 13C CPMAS spectrum of a crashed tablet containing 2.5 w/w% Org OD 14 13C labeled at the 19- and 20-ethynyl and the 21-methyl carbons. The vertical scale in (a) and (b) has been expanded about three times relative to (c) to allow visualization of the unlabeled Org OD 14 13C resonances. 

Current textbooks state that antidepressants are 20% to 40% more effective than placebo, achieving an average 60% response rate compared to placebo response rates of between 20% and 40% Dubovsky, Davies, Dubovsky 2001 Gelder, Mayou, Cowen 2001). The Royal College of Psychiatrists information leaflet states that antidepressants produce substantial improvement in 50-65% of people compared with 25-30% of people given placebo tablets (Royal College of Psychiatrists 2007). 

Two teams of volunteers rate the effectiveness of either an active herbal analgesic or a placebo for the treatment of mild pain. The design is unpaired - one team are allocated to active and the other to placebo tablets. The scale used to report effectiveness is ... 

Manesty Accelacota 24 in., 300-mg Propranolol HC1 Tablets Manesty Premier 200, Placebo Tablets... 

This can only be regarded as a useful clue even tablets with well-known brand names may be faked, and placebo tablets are sometimes made. Every laboratory should maintain a reference collection of authentic tablets and capsules and reference can be made to published collections of tablet identification data. If the container bears the name of the pharmaceutical manufacturer a telephone call giving the details of the tablets (even if they are unmarked white ones) may enable the firm to suggest a limited number of tiieir products sold in that form. Especial care is required with capsules because tiieir contents may readily be changed. (Arsenic, cyanide, and lysergide have been substituted in the past.)... 

---